Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zoster vaccine recombinant, adjuvanted

A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:herpes zoster subunit vaccine GSK 1437173A
herpes zoster vaccine 1437173A
HZ/su vaccine GSK 1437173A
US brand name:Shingrix
Code name:1437173A
GSK 1437173A
GSK1437173A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search